Related Experiment Videos
Bambuterol: effective in nocturnal asthma
G R Petrie1, J Y Chookang, W U Hassan
1Cameron Hospital, Windygates, U.K.
Respiratory Medicine
|November 1, 1993
Summary
Bambuterol significantly improved lung function and reduced nighttime asthma symptoms in patients. This study suggests bambuterol is an effective treatment for nocturnal asthma, enhancing sleep quality.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Nocturnal asthma significantly impacts patient quality of life.
- Patients often remain symptomatic despite standard inhaled therapies, including corticosteroids.
Purpose of the Study:
- To evaluate the efficacy of bambuterol in patients with symptomatic nocturnal asthma.
- To assess bambuterol's effect on overnight peak expiratory flow (PEF) and nocturnal symptoms.
Main Methods:
- A randomized, double-blind, cross-over study comparing bambuterol 20 mg nocte with placebo.
- 28 patients with nocturnal asthma and overnight PEF decline were enrolled.
- Treatment periods lasted 14 days each, with a 14-day run-in period.
Main Results:
- Bambuterol improved mean PEF on waking by 16% (p=0.0002) and evening PEF by 10% (p=0.01).
- Reduced nocturnal awakenings (1.1 to 0.7/night, p=0.01) and beta-2 agonist use (2.7 to 2.1 puffs, p=0.0004).
- Significantly decreased nocturnal cough, wheeze, dyspnea, and improved sleep quality.
Conclusions:
- Bambuterol 20 mg nocte provides effective 24-hour bronchodilation for nocturnal asthma.
- Bambuterol demonstrates a therapeutic role in managing symptomatic nocturnal asthma.
- The drug improved key asthma control metrics and patient sleep quality.